S H Kelkar & Company Ltd
S H Kelkar & Company Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
European business expected to grow rapidly with new factory capacity enabling double-digit growth in next few years. Confident to achieve Rs.
From S H Kelkar & Company Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- European business expected to grow rapidly with new factory capacity enabling double-digit growth in next few years. (Page 12)
- India and Asia markets to continue steady growth, with strong demand in India and Middle East. (Pages 10-12)
- Middle East and APAC regions expected to provide 3-4 years of rapid revenue growth. (Page 12)
- UK and US markets are longer-term growth drivers (3-4 years to ramp up), with large market opportunities. (Page 12)
- Inflationary environments benefit market share gains; demand may be muted overall but company expects normal growth through share gains. (Page 15)
- Confident of maintaining or surpassing FY2025 EBITDA levels in FY2027, indicating revenue growth support. (Page 15)
2 more points management made on revenue & sales performance
Profitability & Margins
See what S H Kelkar & Company Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- FY27 capex is expected to be around Rs. 140 crore, mostly front-ended in the first two quarters.
- Almere factory (Netherlands) is fully operational, supporting European growth by debottlenecking capacity constraints.
- Vanavate facility in Maharashtra expected to come on stream in the coming months, with the transition between factories happening over the next 6-12 months.
- Rebuilding of the Vashivali factory is underway after a fire incident, adding to capex needs.
- Three new development centers (Germany, Manchester UK, and US), with combined annual operating costs of Rs. 80-85 crore, are ongoing strategic investments expected to breakeven after 3-4 years.
2 more points management made on capital expenditure plans
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what S H Kelkar & Company Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company has a secure order book for the next six months, supported by price increases and supply contracts, especially for Q1 and Q2 of FY27.
- They have adequate raw material inventory to ensure supply continuity and margin maintenance.
- Due to inflation and supply chain volatility, they have a robust system to monitor orders and pricing, communicating frequently with clients.
- There is strong demand and good win rates for product range developments, indicating a healthy pending order pipeline.
2 more points management made on order book & pipeline
S H Kelkar & Company Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹650 Cr, net profit ₹2 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What S H Kelkar & Co.'s management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q4 FY25 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
- Q4 FY23 earnings call →
- Q3 FY23 earnings call →
Others in Chemicals & Petrochemicals this season
- Vipul Organics Ltd (Q4 FY26)
Q4 FY26 (Mar 2026) total revenue: ₹5,262.37 lakhs (Consolidated) . Key concall takeaways from Vipul Organics's Q4 FY26 earnings call — and how it ranks against…
- Chemfab Alkalis Ltd (Q4 FY26)
Chlor Alkali segment: ₹55.63 crore (down 1.21% YoY from ₹56.31 crore) . Key concall takeaways from Chemfab Alkalis Ltd's Q4 FY26 earnings call — and how it…
- Sudarshan Pharma Industries Ltd (Q4 FY26)
Revenue from Operations for Q4 March 2026: ₹220.92 Cr (Page 41) . Key concall takeaways from Sudarshan Pharma Industries Ltd's Q4 FY26 earnings call — and how…
- Innovassynth Technologies (India) Ltd (Q4 FY26)
Order book improved by approximately INR 60 crore during the quarter, indicating strong customer demand and revenue visibility. Key concall takeaways from…
Frequently Asked Questions
What were S H Kelkar & Company Ltd Q4 FY26 results?
European business expected to grow rapidly with new factory capacity enabling double-digit growth in next few years. Confident to achieve Rs.
What is S H Kelkar & Company Ltd share price analysis?
S H Kelkar & Company Ltd currently shows a neutral. The stock trades at a P/E of 50.0 with a market cap of ₹2,363 Cr. Investors should review the full earnings analysis for detailed insights.
Is S H Kelkar & Company Ltd planning capital expenditure?
FY27 capex is expected to be around Rs.
Keep S H Kelkar & Company Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.